Kidney Cancer
FY23 Ad Hoc Programmatic Reviewers:
Michael Serzan, M.D.
Dana-Farber Cancer Institute
Last updated Wednesday, September 3, 2025
Michael Serzan, M.D.
Dana-Farber Cancer Institute
Last updated Wednesday, September 3, 2025